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Abstract
Invasive fungal infections are on the rise. Echinocan-
dins are a relatively new class of antifungal drugs that
act by inhibition of a key enzyme necessary for in-
tegrity of the fungal cell wall. Currently there are three 
available agents: caspofungin, micafungin and anidula-
fungin.
while the individual echinocandin antifungals have
a different spectrum of licensed indications, basically
all  of  them  are  available  for  the  treatment  of  can-
didemia and invasive candidiasis. antifungal treatment
modalities basically include in therapy for suspected or
proven infection and prophylaxis. all three drugs are
comparatively  expensive.  Therefore  a  systematic  re-
view of the literature was performed to investigate the
following aspects:
• general aspects of cost-effectiveness in the treat-
ment of invasive fungal infections 
• Cost-effectiveness of the treatment with the above-
mentioned antifungals
• Cost-effectiveness in two settings: therapy and pro-
phylaxis 
Early initiation of antifungal therapy, adjustment af-
ter availability of microbiological results, duration of
therapy, success and occurrence of severe complica-
tions (e.g. renal failure) are the most important cost
drivers in antifungal therapy.
Considering the specific antifungals, for caspofun-
gin the best evidence for cost-effectiveness is found
in  treatment  of  invasive  candidiasis  and  in  empiric
therapy of suspected infections. favourable economic
data are available for micafungin as a cost-effective al-
ternative  to  lamB  for  prophylaxis  in  patients  with
hematopoietic stem cell transplantation (HsCT).  for
anidulafungin, cost-effectiveness was demostrated in a
pharmacoeconomic model.  net savings – yet not sig-
nificant – were observed in a retrospective chart re-
view of 234 patients. generally, however, most analy-
ses  are  still  based  on  pharmacoeconomic  modelling
rather than direct analysis of trial data or real-life clini-
cal populations.
as an overall conclusion, using caspofungin, mica-
fungin, or anidulafungin is not more expensive than
using  other  established  therapies.  Micafungin  has
proven to be cost-effective in prophylaxis if the local
fungal  epidemiology  indicates  a  high  level  of  resis-
tance to fluconazole. switch strategies involving early
initiation  of  broadly  active  therapy  with  switch  to
cheaper alternatives according to microbiology results
and clinical status and early initiation of an appropri-
ate therapy have been proven to be cost-efficient inde-
pendent of the antifungal agent.
List of  abbreviations: 
HsCT = hematopoietic stem cell transplantation
fnP = febrile neutropenia
lamB = liposomal amphotericin B
ICu days = treatment days on an intensive care unit
los = length of stay in hospital
daC = drug acquisition cost
EI = early initiation of therapy
doT = duration of therapy
CEa = cost-effectiveness analysis
Qaly = quality adjusted life-year
IRf = impaired renal function
C/IC = Candidemia / invasive candidiasis
InTRoduCTIon
Invasive fungal infections are on the rise. Convention-
al amphotericin B (c-amB) and azole antifungals have
been the mainstay of antifungal therapy into the last
decade. The high incidence of infusion-related toxicity
and  nephrotoxicity  associated  with  camB  and  the
emergence of fluconazole-resistant strains of Candida
glabrata prompted a search for alternatives. Echino  -
candins are a new class of antifungal drugs that act by
inhibition of beta-(1,3)-d-glucan synthase, a key en-
zyme necessary for the integrity of the fungal cell wall.
Caspofungin was the first drug licensed drug in this
class. It is indicated for esophageal candidiasis, can-
didemia, invasive candidiasis, empirical therapy in pa-
tients with febrile neutropenia and may be used for
salvage therapy in patients with invasive aspergillosis.
Response rates are generally comparable to those of
amphotericin  B  and  fluconazole.  Micafungin  is  pre  -
sently  approved  for  esophageal  candidiasis,  invasive
candidiasis including candidemia and for prophylaxis
of Candida infections in patients undergoing allogene-
ic  HsCT.  The  currently  approved  indications  for
anidulafungin  are  esophageal  candidiasis,  candidemia
and invasive candidiasis. The incidence of infusion-re-
lated adverse effects and nephrotoxicity is much lower
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6) Wilke_Umbruchvorlage  23.03.11  12:39  Seite 180with  echinocandins  than  with  amphotericin  B.  and
echinocandins show a good safety profile in patients
with IRf. Even though they are clearly a better choice
than amphotericin B pharmacoeconomically, the high-
er cost of these drugs in comparison to azole antifun-
gals may attenuate their use as first-line agents in inva-
sive fungal infections [1]. 
looking  at  the  therapeutic  cost  of  fungal  infec-
tions, several cost drivers can be identified. The attrib-
utable  costs  for  patients  suffering  from  candidemia
are significant and range between ﾣ8,252 and ﾣ16,595
in one analysis [2] and usd34,123 and usd 44,536 in
another study [3].
whether  any  given  antifungal  therapy  is  an  eco-
nomically  adequate  option  depends  on  its  effect  on
the cost drivers. as echinocandins are relatively costly,
daC is considered an influencing factor on total cost
[4]. However some authors find that daC is not influ-
encing total cost [5] or other factors outweigh daC
[6].
Cost considerations also play an increasingly impor-
tant  role  in  determining  the  practical  usefulness  of
medications. a number of studies have shown that the
overall  expenses  associated  with  the  treatment  of
C/IC are significant and are largely driven by hospital-
ization costs. Especially los is an important cost dri-
ver [7-10].
This article provides a review of the current litera-
ture on the role of echinocandins in the treatment or
prophylaxis of fungal infections from the economical
perspective.
MaTERIals and METHods
we  conducted  a  literature  review  to  investigate  the
available evidence on cost-effectiveness of antifungal
strategies in proven invasive candidiasis, suspected in-
fection  and  prophylaxis.  Concerning  the  economical
impact of antifungal therapy with echinocandins, sev-
eral factors were identified as influencing the total cost:
• duration of therapy (doT) [5]
• adjustment of therapy after availability of microbi-
ological results [4, 11]
• drug acquisition cost (daC) [12-13]
• early initiation of treatment (EI) [14]
• complications, such as renal failure or hepatotoxi  -
city [13, 15]
• therapeutic success [16-18]
from a healthcare system perspective, there are es-
tablished  methods  in  CEa  to  determine  whether  a
new drug should be reimbursed by the public health
system or not. one – yet not undisputed – indicator is
Qalys [19-22].
with respect to these known major cost drivers, we
conducted a literature review focussed on articles deal-
ing with echinocandins in the context of cost issues or
cost-impacting factors.
we used the name of the antifungal agent and
‘cost-effectiveness’ oR ‘economical’ as search terms.
REsulTs
The MEdlInE search yielded a total of 17 articles.
Three additional analyses were included from poster
presentations on international congresses where publi-
cation is in progress (fig. 1). The number of publica-
tions referring explicitly to cost-effectiveness or eco-
nomical analyses is the highest for caspofungin.
In  addition  we  performed  a  literature  search  on
general aspects like complications, rationales for em-
piric therapy and therapy adjustments due to microbi-
ology findings. from this search 7 more relevant arti-
cles  were  retrieved.  The  following  section  describes
major findings for the three echinocandins and results
concerning general economical aspects of C/IC thera-
py.
CasPofungIn
Most CEas were performed for caspofungin. Two ar-
ticles  were  excluded  because  they  involved  patients
with invasive aspergillosis. Two articles evaluated the
cost-effectiveness of caspofungin in candidemia [23-
24]. wingard et al. described favourable effects of us-
ing  caspofungin  instead  of  lamB.  The  authors  de-
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Fig. 1. Results or the literature search for cost-effectiveness of echinocandins. * analyses for anidulafungin as poster presenta-
tions, one article in press.
Search findings on ”cost effectiveness“ and ”economical“
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using caspofungin.  The effect was mainly caused by
the lower incidence of IRf in the caspofungin group.
Treatment with caspofungin was found to be a cost-
saving strategy for a hospital. sidhu et al. directly com-
paried  micafungin  vs.  caspofungin.  The  CEa  was
based on data of a clinical trial comparing both agents.
The costs for treatment of invasive candidiasis were
ﾣ29,095 for micafungin vs. ﾣ29,953 for caspofungin.
There were remarkably lower costs for micafungin in
the group of successfully treated patients (ﾣ48,771 vs.
ﾣ52,066). However, the differences were not statisti-
cally significant.
Three articles described CEas in patients with neu-
tropenic fever [5, 13, 25].  al-Badriyeh et al. found
caspofungin to be a cost-saving alternative compared
to  lamB.  savings  of  au$  7,245  per  patient  were
demonstrated.  stam  et  al.  found  caspofungin  to  be
cost-effective  as  treatment  costs  were  €  8,351  for
caspofungin vs. € 11,821 for lamB. The model was
based on a clinical trial with a head-to-head compari-
son of both drugs. wingard et al. found caspofungin
to cause usd 5,326 less costs than lamB in the treat-
ment of neutropenic fever. This was based on a com-
bined effect of lower daC and lower IRf-rates when
using caspofungin.
Two  CEas  evaluated  the  use  of  caspofungin  in
ICu patients with suspected fungal infection [6, 26].
Bruynesteyn et al. designed a model that was derived
from clinical trial data. It included also costs for IRf.
The  results  showed  costs  of  ﾣ  9,762  for  treatment
with caspofungin, which was ﾣ 2.033 lower than for
the treatment with lamB. Caspofungin also showed
advantages in terms of life years saved (Qaly). golan
et al. compared different treatment strategies for ICu
patients  with  suspected  Candida infections.  The  au-
thors compared a caspofungin strategy with a flucona-
zole strategy. The outcome measures were mortality
and cost for discounted life year respectively. as a re-
sult, fluconazole turned out to be the more reasonable
empiric strategy (usd 12,593 per life year saved and
reduction of mortality from 44.0% to 30.4%. Caspo-
fungin is the more effective strategy but causes usd
295,115 of costs per life year saved. However, caspo-
fungin is the more effective strategy if fluconazole re-
sistance among Candida species in a hospital is >25%.
MICafungIn
we found 6 articles on CEas investigating the use of
micafungin. Two articles evaluated the use of micafun-
gin in candidemia or invasive candidiasis [24, 27]. Cor-
nely et al. assessed the economic impact of using mi-
cafungin vs. lamB in candidemia and invasive can-
didiasis. Micafungin was found to be a cost-effective
alternative causing total treatment cost of € 43,243 vs.
€ 49,216. Moreover the study showed that more pa-
tients could be successfully treated with micafungin vs.
lamB  (52.9%  vs.  49.1%).  The  study  performed  by
sidhu et al. [20] was already described in the caspofun-
gin section.
as micafungin is licensed for prophylaxis in patients
undergoing allogeneic HsCT we also searched for pub-
lications evaluating the use of micafungin in this indi-
cation. we found three articles dealing with economic
aspects of micafungin in prophylaxis [28-30]. 
nomura et al. designed a hypothetical cohort of 40-
year old patients with acute myeloic leukemia under-
going chemotherapy. He investigated the economical
effects of three different strategies. (1) oral flucona-
zole, (2) intravenous amphotericin B when fever is de-
tected and (3) no general prophylaxis but use of mica-
fungin if fungal infection occurs. outcome measures
were years of life survived (yls) and incremental cost
per yls. The fluconazole strategy caused the highest
cost per patient but also the highest amount of life
years  saved.  strategy  (1)  caused  costs  of  usd
625/yls vs. strategy (3) and usd 652/yls vs. strate-
gy (2). The authors concluded that a prophylaxis strat-
egy using oral fluconazole appeared to ensure clinical
benefit with an acceptable cost-effectiveness. 
sohn et al. investigated two different strategies for
patients undergoing HsCT. strategy (1) was micafun-
gin 50 mg/d, strategy (2) was fluconazole 400 mg/d
given  intravenously.  outcome  measures  were  cost,
number of infection-free patients and life years saved.
The data were derived from clinical studies. The au-
thors  created  a  hypothetical  cohort  of  100  patients
and  tested  the  strategies.  The  micafungin  strategy
saved Kw 95,511,000 (1 usd = 925 Kw by 2007. It
resulted in 0.5 more infection-free patients and 4.8 ad-
ditional life years saved per 100 patients. from these
results, the authors concluded that micafungin is a rea-
sonable prophylaxis strategy for patients undergoing
HsCT in Korea. 
schonfeld et al. investigated the use of micafungin
vs. fluconazole for prophylaxis in patients undergoing
HsCT. The data were derived from a phase III clinical
trial that included 882 patients. a cost analysis from
the  hospital  perspective  was  performed.  additional
sensitivity analyses were conducted by varying several
cost factors. The primary analysis included data from
882 patients (527 males, 355 females; micafungin, 425
patients, mean age, 43.2 years [range, 0.6-73.0 years];
fluconazole, 457 patients, mean age, 41.9 years [range,
0.6-71.0 years]). Total hospital costs per patient were
usd 121,098 and usd 124,957 in micafungin and flu-
conazole recipients, respectively, a difference of usd
3,859. The bootstrapping analysis found that micafun-
gin prophylaxis was cost-saving in 72.4% of the sam-
ples versus 9.2% with fluconazole prophylaxis. sensi-
tivity analyses of estimated hospital costs found that
micafungin was a cost-effective therapy.
one article reported on the use of micafungin for
suspected  ICu-acquired  candidemia  among  patients
with sepsis [16]. In this study, a hypothetical cohort of
1,000  patients  with  suspected  ICu-acquired  can-
didemia (ICu-aC) was designed. The strategies were
either empirical therapy with micafungin (MIC), em-
pirical therapy with fluconazole (flu) or no treatment
with  a  watchful  waiting  strategy.  differences  in  sur-
vivors, drug acquisition cost and cost per Qaly were
examined  and  calculated  respectively.  The  data  were
derived  from  clinical  trials.  Cost  data  were  obtained
from a clinical centre in the us. The base case analysis
assumed  an  ICu-aC-attributable  mortality  of  40%
and a 52% relative risk reduction in mortality with ap-
propriate  timely  therapy,  compared  with  flu  (total
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results in 4 fewer deaths at an incremental cost per
death  avoided  of  $61,446.  similarly,  in  a  reference
case, the incremental cost-effectiveness of MIC over
flu was $34,734 (95% confidence interval $26,312 to
$49,209) per Qaly. The estimates were most sensitive
to the Qaly adjustment factor and to the risk of can-
didemia among septic patients. from these results, the
authors concluded that MIC is a reasonable strategy
for ICu-aC.
anIdulafungIn
Three economic analyses for anidulafungin were pre-
sented on different international congresses. one Pub-
lication in a peer-reviewed journal is in press [17-18,
31-32].
Earnshaw  et  al.  developed  a  pharmacoeconomic
model with a decision tree structure and assessed cost
from a us third party payer’s perspective. a cohort of
patients was generated with 58 years of mean age and
proven candidemia or other evidence of invasive can-
didiasis.  Input  parameters  including  success  rate,
doT, los and others were taken from a randomized
controlled trial [33]. Cost data were derived from pub-
lications and a large us-hospital database.
as a result, anidulafungin turned out to be a cost-
effective therapy alternative compared to standard-of-
care (usd 73,000 vs. usd 81,000). The main drivers
for the favourable result with anidulafungin – despite
higher daC – were higher success rate, lower mortali-
ty, shorter los. one-way sensitivity analysis was per-
formed to test the robustness of the model. no data
on the number of iterations and the included variables
are published so far.
Reboli et al. performed an economic evaluation of
their own data from the randomized controlled trial
of  anidulafungin  versus  fluconazole  [33],  that
showed a significantly higher overall success rate for
anidulafungin  in  the  protocol-defined  primary  end-
point [33]. Resource consumption data were collected
by medical chart reviews. In cases without available
charts (75 of 234 patients), two alternative methods
were used for cost estimation: expert assessment or
regression analysis comparing the patients with avail-
able  medical  records  versus  the  patients  without
records. Results showed that anidulafungin was a cost-
effective  therapy  alternative  to  intravenous  flucona-
zole. Both approximation methods revealed cost sav-
ings  of  usd  2,223  (expert  assessment)  and  usd
2,681 (regression), respectively, for anidulafungin. In-
terestingly, this is one of the rare studies in which real
cases were analyzed retrospectively and no modelling
approach was chosen. However, data from one third
of the patients were not complete and the cost differ-
ence failed to show significance (p = 0.70 in both ap-
proaches).
garcia et.al.[31] presented a pharmaco-economical
evaluation of the three currently available echinocan-
dins in a spanish hospital setting. anidulafungin thera-
py was found to have a lower drug acquisition cost per
episode (€6000) than other echinocandins, for which
costs are influenced by the potential requirement for
dose adjustments.
Treatment costs with caspofungin were reported to
range from €4281 to €7991, depending on the specific
dose requirements based on patient weight and hepatic
function. drug acquisition costs with micafungin were
estimated  at  either  €6000  (using  a  dose  of  100
mg/day)  or  €10  741  (in  cases  where  inadequate  re-
sponse requires a dose increase to 200 mg/day).
The authors concluded that treating C/IC in adult,
non-neutropenic  patients  with  anidulafungin  was  a
cost-saving  option,  and  also  allowed  better  budget
control.
an analysis regarding the special cohort of critically
ill  ICu-patients  was  performed  by  Reboli  et.al.[32].
for patients in the ICu at treatment initiation, anidula-
fungin exhibited a definite but non-significant trend
towards lower costs, which was driven by reductions in
ICu and hospital lengths of stay. after adjustment for
baseline covariates, those ICu patients who received
anidulafungin as first-line therapy for C/IC gained a
significant advantage in the number of hospital-free
days (18.2 vs. 4.3 days; p 0.04).
other potential economical benefits can be derived
from the overall profile of this echinocandin [34-35].
Particularly, the reportedly low toxicity leads to the as-
sumption that it can be cost-effective in the treatment
of  invasive  candidiasis.  as  the  authors  recommend
anidulafungin particularly if a very low drug-interac-
tion potential is needed, this could be another factor
which leads to economically favourable results.  
gEnERal fIndIngs on EConoMICal EffECTs of
anTIfungal THERaPy
Besides articles investigating one of the echinocandins
directly we searched for strategies or influencing fac-
tors that generally affect treatment cost of antifungal
therapy. we retrieved five articles that revealed effects
possibly  influencing  cost  [4,  11,  36-38].  Empirical
therapy with a potent antifungal agent in patients with
suscepted invasive candidiasis is an established strate-
gy and echinocandins are useful and cost-effective in
this setting. However, since methods for rapid species
differentiations are available and save early detection
of the fungus strain and its resistance patterns is enor-
mously  important.  fluorescent  in  situ  hybridisation
(fIsH) assay is a proven method for the differentia-
tion Candida strains [39]. forrest et al. and alexander
et al. investigated the potential economical benefit of
early detection of the causative Candida strain. If a
susceptible species is detected, therapy may be deesca-
lated from an expensive echinocandin to fluconazole
after clinical improvement. alexander et al. found that
the use of fIsH would save usd 1,837 per patient
treated while forrest et al. calculated savings of usd
1,729 per patient. In these investigations, the savings
resulted from a reduction in cost for caspofungin. of
course,  the  results  would  be  similar  with  other
echinocandins.
Bates et al. designed a study based on real-life hos-
pital cases and investigated the occurrence and cost of
renal failure in 707 patients treated with amphotericin
B:  212 (30%) of 707 adult patients receiving ampho-
tericin B developed renal failure. overall mortality in-
creased from 16% to 54% in patients with renal fail-
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and additional costs of usd 29,823 occurred. If pa-
tients already suffer from IRf, echinocandins are defi-
nitely  the  recommended  alternative  as  they  show  a
better  safety  profile  for  these  patients  compared  to
polyene antifungals [40].
Moreover,  as  the  antifungal  therapy  is  costly  and
clinicianﾴs knowledge of therapeutic strategies is vari-
able, regular audits have been found to be effective in
optimizing  antifungal therapy and saving costs. Ray-
mond et al. [37] set up an audit for the use of expen-
sive systemic antifungals in a french university hospi-
tal. They investigated the prescription patterns in 81
patients  receiving  118  antifungal  prescriptions.  al-
though the initiation of therapy itself was justified in
92% of the prescriptions, the chosen regimen was ap-
propriate  in  only  54%  according  to  local  guidelines.
The  authors  found  an  overuse  of  caspofungin  and
dosing  errors  of  voriconazole  in  paediatric  patients.
They concluded that the audit results stress the need
to update local recommendations. 
finally  arnold  et.al.[38]  showed  that  appropriate
treatment is an important independent cost driver in
the therapy of C/IC. The population of patients was
derived  from  a  single-center  retrospective  chart  re-
view analysis. appropriate therapy was defined as pre-
scription and delivery of an antifungal agent to which
the isolated pathogen was sensitive within 24h of pos-
itive culture. In addition the dosage ought to be ade-
quate. data were analysed for 167 patients (22 in the
appropriate therapy group and 145 in the inappropri-
ate therapy group). Postculture los was shorter in
the appropriate therapy group (mean 7 vs 10.4 days,
p=0.037).  This  correlated  with  total  hospital  costs
that  were  lower  in  the  appropriate  therapy  group
(mean  $15,832  vs  $33,021,  p<0.001.)  a  graded  in-
crease in costs was noted with increasing number of
modifiable risk factors (p=0.001). The authors con-
cluded that inappropriate therapy for C/IC occurring
within 14 days of hospitalization was associated with
prolonged los and increased costs. a rise in costs,
but not los, was noted with increasing modifiable
risk factors. 
Table 1 summarizes the data indicating a positive
influence of echinocandins on cost drivers and influ-
encing factors.
Table 2 shows general strategies that showed to be
cost-saving in the setting of C/IC-therapy.
dIsCussIon
Caspofungin  and  micafungin  are  well  investigated  in
terms of pharmacoeconomical aspects. However, most
analyses still are models using data derived from clinical
trials. Taking this  into account [20, 41], these two anti-
fungals can be considered cost-effective in their respec-
tive indications. Most authors admit that the results of
their models are highly sensitive to changes in some
cost-associated factors. usually, sensitivity analyses or
Monte Carlo simulations are used to assess the robust-
ness of the assumptions in a pharmacoeconomic mod-
el. as these analyses were performed in all studies cited
above, the results can be considered quite reliable. 
when using models and scenario-apporaches, sig-
nificant savings were found. Retrospective case analy-
sis  did  show  for  anidulafungin  better  response  with
slightly higher cost, yet results were not significant. 
However, a subgroup of ICu patients (retrospec-
tive analysis) is clearly showing favourable results for
anidulafungin. Thus it can be concluded that especially
critically ill patients benefit clinically and economically
when treated with anidulafungin.
The  positive  trend  towards  cost-effectiveness  of
anidulafungin should be verified via further research
and analyses. 
Considering the treatment of suspected infections,
adaptation of strategies to local epidemiology and re-
sistance patterns appears crucial. once the rate of a
fluconazole-resistant Candida strains in a clinical cen-
ter exceeds 25%, echinocandins should be considered
a cost-effective empiric treatment choice.
ConClusIon
The  economic  impact  of  antifungal  therapy  with
echinocandins  is  an  increasingly  important  issue,  as
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Table 2. general aspects of C/IC-therapy. Proven cost-effective strategies in the Management of C/IC.
de-escalation of initial therapy after micribiological differentiation
Regular clinical audits of antifungals utilization and regular updates of treatment algorithms
appropriate (early and right-dosed) effective antifungal therapy
Table 1. summary of potential economic effects of the echinocandins. x = potential reduction of total treatment cost vs. more
traditional antifungals.
Parameter/agent Caspofungin Micafungin Anidulafungin
cost-effectiveness in invasive candidiasis/candidemia xx x
cost-effectiveness in suspected infections xx
lowering the incidence of IRf xx x
cost-effectiveness in prophylaxis x
6) Wilke_Umbruchvorlage  23.03.11  12:39  Seite 184the number of fungal infections in critically ill patients
and immunocompromised patients is constantly grow-
ing [42-43] and these infections are asscociated with
extremely  high  total  cost  of  treatment  [2-3].  The
analysis of the current literature shows that therapy
with echinocandins is generally cost-effective and may
even be associated with net savings although drug ac-
quisition cost are higher than with conventional thera-
py regimens. Currently, favourable cost effects are best
documented for caspofungin. a number of pharma-
coeconomic  analyses  are  available  for  micafungin.
some  poster  presentations  are  available  for  anidula-
fungin and one study is in press. Moreover there are
general clinical strategies to be further investigated and
discussed [44]. Particularly early specific determination
of the causative strain, therapies that consider renal
function, regular audits and early appropriate therapy
were also proven to be cost-effective strategies in anti-
fungal therapy. In prophylaxis, the optimal strategies
depend on local epidemiology and resistance patterns.
future clinical studies should incorporate economical
aspects in the initial design.
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